Stifel resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $85 price target The firm sees Revolution being “on the cusp of majorly disrupting” the standard of care in pancreatic ductal adenocarcinoma and expects other indications to follow in years to come, calling the overall total addressable market “massive.” The firm models first revenue for Revolution in Q1 of 2027 and global revenue of $11.3B by 2035, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Erasca initiated with a Buy at Stifel
- 3 Stocks Flashing Strong Buy Alerts, According to Technical Analysis
- Revolution Medicines appoints Alan Sandler as CDO
- Revolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
- Revolution Medicines price target raised to $71 from $70 at JPMorgan